Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMT310 Phase 2b in Acne Vulgaris
NCT04106778Phase 2Completed
- Sponsor
- Dermata Therapeutics
- Start
- Oct 2019
- Primary completion
- May 2020
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing DMT310 with Placebo (2 arms). Primary endpoints: Change from Baseline in Inflammatory Lesion Counts at 12 weeks and Investigator Global Assessment Success at 12 weeks. Started Oct 2019; status: completed.
02
Drugs
DMT310
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04106778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106778.